Biora Therapeutics Inc

NASDAQ:BIORUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.

Contact Information

Headquarters

4330 La Jolla Village Drive, Suite 200SAN DIEGO, CA, United States 92122

Phone

760-494-1555

Fax

248-848-1623

Executives

Independent Chairman of the Board

Jeffrey Alter

Chief Executive Officer, Director

Aditya Mohanty

Chief Financial Officer

Eric d'Esparbes

Senior Vice President, General Counsel, Secretary

Clarke Neumann

Independent Director

Jeffrey Ferrell